Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,122

Document Document Title
WO/2018/007973A2
Disclosed is a new process and intermediates for preparing benzoxazepines of Formula (I): (I) wherein Q is, and A, L, B, RA and m are as defined herein.  
WO/2018/009417A1
Disclosed herein are small molecule calpain modulator compositions, pharmaceutical compositions, the use and preparation thereof. Some embodiments relate to macrocyclic α-keto amide derivatives and their use as therapeutic agents.  
WO/2017/222083A1
The present invention provides compounds of formula (I) and pharmaceutically acceptable salts thereof, wherein n, X1, X2, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12and R13 are as defined in the specification, processes for their p...  
WO/2017/215600A1
Provided are a substituted tricyclic herteocyclic compound of formula I or a stereoisomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt, ester or a prodrug thereof, a pharmaceutical compo...  
WO/2017/205536A2
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compou...  
WO/2017/205536A3
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical composition...  
WO/2017/132752A1
A loxapine film oral dosage form includes loxapine salt, free base, or prodrug in an amount effective to provide relief from acute agitation associated with schizophrenia or bipolar 1 disorder via oral transmucosal delivery, dispersed in...  
WO/2017/098430A1
The present invention relates to a new chemical synthesis, intermediates and catalysts useful for the preparation of the neprilysin (NEP) inhibitor sacubitril. It further relates to new intermediate compounds and their use for said new c...  
WO/2016/203401A1
The present invention relates to aryl analogs, pharmaceutical compositions containing them and their use as Nrf2 regulators.  
WO/2016/198366A1
The instant invention relates to novel conjugates of formula (I): S - L - A (I) or salts thereof, wherein A is a gamma-secretase inhibitor, L is a linker and S is a peptidase-specific substrate, as well as processes for their manufacture...  
WO/2016/149581A1
Provided herein are compounds of formula (I) useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2016/126725A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:, where R, L, X1, X2, X3, X4, Y1, Y2, Y...  
WO/2016/126722A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I: (Formula I should be inserted here) wh...  
WO/2016/126726A1
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formulae I or Formula II: where R, L, X1, X2, X3,X4, X5, Y1, Y2, ...  
WO/2016/126721A1
The present invention relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with HDAC6, having a Formula I:(Formula I should be inserted here), where R, L, X1, X2...  
WO/2016/126724A1
The present disclosure relates to inhibitors of zinc-dependent histone deacetylases (HDACs) useful in the treatment of diseases or disorders associated with an HDAC, e.g., HDAC6, having a Formula I:(Formula I should be inserted here) whe...  
WO/2016/087370A1
The present invention relates to derivatives of formula (I) wherein (R1)n, ring (A), Y1, Y2, X, R4, L1, L2, and Ar1 are as described in the description, to their preparation, to pharmaceutically acceptable salts thereof, and to their use...  
WO/2016/075239A1
The invention relates to aryl and heteroaryl-fused tetrahydro-1,4-oxazepine amide derivatives of general formula (l),which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders relat...  
WO/2016/075240A1
The invention relates to morpholine and 1,4-oxazepane amide derivatives of general formula (I), which are agonists of somatostatin receptor subtype 4 (SSTR4), useful for preventing or treating medical disorders related to SSTR4. In addit...  
WO/2016/055028A1
The present invention relates to compounds of formula (I): and to salts thereof, wherein A has any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300....  
WO/2016/019588A1
Compounds, compositions, and methods for treating C. difficile are provided.  
WO/2016/012333A1
A method of combating and controlling insects, acarines, nematodes or molluscs which comprises applying to a pest, to a locus of a pest, or to a plant susceptible to attack by a pest an insecticidally, acaricidally, nematicidally or moll...  
WO/2015/138500A1
A genus of arylsulfonamide derivatives of aminocycloalkanols is disclosed. The compounds are of the following genus (I):. The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2A and, as a consequen...  
WO/2015/123519A9
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2015/123519A3
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2015/123519A2
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2015/123519A8
The present disclosure provides processes for the preparation of a compound of formula: which is a selective late sodium current inhibitor. The disclosure also provides compounds that are synthetic intermediates.  
WO/2015/110826A1
The present disclosure relates to certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamide compounds (including pharmaceutically acceptable salts thereof), (Formula (I)) that inhibit dipeptidyl peptidase 1(DPP1) activity,...  
WO/2015/109130A1
Provided herein are compounds useful for the treatment of HBV infection in a subject in need thereof, pharmaceutical compositions thereof, and methods of inhibiting, suppressing, or preventing HBV infection in the subject.  
WO/2015/056782A1
The purpose of the present invention is to provide a novel compound having ACC2-inhibiting activity and to provide a pharmaceutical composition comprising said compound. A compound indicated by formula (in the formula, R1 indicates a sub...  
WO/2014/133414A3
1. Compounds of general formula I, or racemic mixtures thereof, or individual optical isomers thereof, or pharmaceutically acceptable salts and/or hydrates thereof, wherein: X is the amino group R'R''N, optionally substituted or unsubsti...  
WO/2014/125444A1
Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.  
WO/2014/057080A2
The present invention is directed to novel cyclic amines which inhibit the P2X7 receptor.  
WO/2014/057439A3
Piperazine compounds or their pharmaceutically acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof are provided. The pharmaceutical compositions comprising an effective amount of piperazine ...  
WO/2014/057080A3
The present invention is directed to N-(2-(cyclic amine)ethyl)benzamide derivatives of formula (I), as P2X7 inhibitors, pharmaceutical compositions comprising said compounds and uses of the compounds to treat pain, inflammation, neurolog...  
WO/2014/023708A1
There are provided compounds of the formula (1) wherein W, X, Y, Z, R1, R2, R3, R4, R5 and R6 are described herein. These compounds are useful for the treatment of proliferative diseases, including cancer.  
WO/2013/119564A1
It has been determined that co-administration of a rifamycin and a switch-region inhibitor 1) results in synergistic antibacterial effects, enabling efficacy at low, subtoxic doses, and/or 2) results in a low spontaneous resistance frequ...  
WO/2013/112809A3
25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof is provided. Methods of treatment of bowl related disorders using isolated and/or purified 25-desacetyl rifaximin or a pharmaceutically acceptable salt thereof are also...  
WO/2013/100158A1
An actinic ray-sensitive or radiation-sensitive resin composition, which is excellent in sensitivity, resolution, a pattern profile and a depth of focus (DOF), and, an actinic ray-sensitive or radiation-sensitive film and a pattern formi...  
WO/2013/064231A1
The invention provides modulators for the orphan nuclear receptor RORγ and methods for treating RORγ mediated diseases by administration of these novel RORγ modulators to a human or a mammal in need thereof. Specifically, the present ...  
WO/2013/033245A1
The oxidative functionalization of olefins is a common method for the formation of vicinal carbon-heteroatom bonds. However, oxidative methods to transform allenes into synthetic motifs containing three contiguous carbon-heteroatom bonds...  
WO/2013/006463A1
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...  
WO/2013/006485A1
The present disclosure relates to compounds that are sodium channel inhibitors and to their use in the treatment of various disease states, including cardiovascular diseases and diabetes. In particular embodiments, the structure of the c...  
WO/2012/167171A2
The present invention relates generally to olefin metathesis. In some embodiments, the present invention provides methods for Z-selective ring-closing metathesis.  
WO/2012/161622A2
The invention relates to the field of medicinal chemistry, pharmacology and medicine and contains a description of pharmaceutical compositions and combination drugs based on secretion stimulators and protectors of incretin hormones for t...  
WO/2012/161622A3
The invention relates to the field of medicinal chemistry, pharmacology and medicine and contains a description of pharmaceutical compositions and combination drugs based on secretion stimulators and protectors of incretin hormones for t...  
WO/2012/152915A1
The present invention relates to benzazepine derivatives of the formula (I) or a physiologically tolerated salt thereof. The present invention also relates to pharmaceutical compositions comprising such benzazepine derivatives, and the u...  
WO/2012/126791A1
The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active com...  
WO/2012/110459A1
This invention relates to compounds of the formula wherein and R1 to R3 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the the...  
WO/2012/070015A9
The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other act...  

Matches 1 - 50 out of 1,122